Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080694 | 0.94 | BTK (0.49) | BTKHDAC6RAD52ACKR3PAX8 | |
| SCHEMBL4081138 | 0.92 | BTK (0.58) | BTKHDAC6 | |
| SCHEMBL4085985 | 0.86 | BTK (0.49) | BTKRAD52ACKR3LCKUBE2N | |
| SCHEMBL4085005 | 0.84 | BTK (0.61) | BTKHDAC6 | |
| SCHEMBL4086332 | 0.83 | BTK (0.48) | BTKHDAC6 | |
| SCHEMBL4080285 | 0.82 | BTK (0.61) | BTKHDAC6 | |
| SCHEMBL4095924 | 0.81 | BTK (0.49) | BTKHDAC6 | |
| SCHEMBL4095342 | 0.81 | BTK (0.39) | BTKHDAC6RAD52L3MBTL1 | |
| SCHEMBL3000846 | 0.80 | BTK (0.70) | BTKHDAC6 | |
| SCHEMBL4090411 | 0.80 | BTK (0.49) | BTKRAD52ACKR3LCKUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885HDAC6 1266/4885RAD52 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.